Literature DB >> 17102106

Current trends in functional imaging of pheochromocytomas and paragangliomas.

Barry L Shulkin1, Ioannis Ilias, James C Sisson, Karel Pacak.   

Abstract

Most pheochromocytomas/paragangliomas should be evaluated with anatomical imaging (computed tomography or magnetic resonance imaging) followed by functional imaging (nuclear medicine modalities). Functional imaging assures that the tumor is indeed a pheochromocytoma/paraganglioma and enables more thorough localization, especially detecting as many lesions as possible (in particular for metastatic disease). Functional imaging for pheochromocytomas/paragangliomas, can use radiolabeled ligands specific for pathways of synthesis, metabolism, and inactivation of catecholamines or nonspecific ligands. In an overview of the available nuclear medicine modalities, we summarize the accumulated experience and recommend when functional imaging should be applied to patients with pheochromocytoma/paraganglioma.

Entities:  

Mesh:

Year:  2006        PMID: 17102106     DOI: 10.1196/annals.1353.041

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  15 in total

Review 1.  ⁶⁸Ga-labelled peptides in the management of neuroectodermal tumours.

Authors:  Meeran Naji; Adil AL-Nahhas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 2.  Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer.

Authors:  Ioannis Ilias; Chaitanya Divgi; Karel Pacak
Journal:  Semin Nucl Med       Date:  2011-09       Impact factor: 4.446

3.  68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours.

Authors:  Meeran Naji; Chunlei Zhao; Sarah J Welsh; Richard Meades; Zarni Win; Annalisa Ferrarese; Tricia Tan; Domenico Rubello; Adil Al-Nahhas
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

Review 4.  A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors.

Authors:  Ioannis Ilias; Karel Pacak
Journal:  Nucl Med Biol       Date:  2008-08       Impact factor: 2.408

Review 5.  Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome.

Authors:  Karel Pacak; Graeme Eisenhofer; Ioannis Ilias
Journal:  Hormones (Athens)       Date:  2009 Apr-Jun       Impact factor: 2.885

Review 6.  Contemporary imaging of incidentally discovered adrenal masses.

Authors:  Milton D Gross; Melvyn Korobkin; Wessam Bou Assaly; Ben Dwamena; Mehdi Djekidel
Journal:  Nat Rev Urol       Date:  2009-06-09       Impact factor: 14.432

Review 7.  Treatment of malignant pheochromocytoma.

Authors:  R Adjallé; P F Plouin; K Pacak; H Lehnert
Journal:  Horm Metab Res       Date:  2009-08-11       Impact factor: 2.936

8.  Diagnosis of pheochromocytoma.

Authors:  Kalpana S Vora; Veena R Shah
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2012-04

9.  Functional Imaging of Pheochromocytoma with Ga-DOTATOC and C-HED in a Genetically Defined Rat Model of Multiple Endocrine Neoplasia.

Authors:  Matthias Miederer; Sara Molatore; Ilaria Marinoni; Aurel Perren; Christine Spitzweg; Sybille Reder; Hans-Jürgen Wester; Andreas K Buck; Markus Schwaiger; Natalia S Pellegata
Journal:  Int J Mol Imaging       Date:  2011-06-08

10.  Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma.

Authors:  Gabriele Parenti; Benedetta Zampetti; Elena Rapizzi; Tonino Ercolino; Valentino Giachè; Massimo Mannelli
Journal:  J Oncol       Date:  2012-07-17       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.